Objective: This study aimed to re-evaluate the effectiveness of antenatal corticosteroids (ACS) and to analyze the association between ACS and the mode of delivery in the context of perinatal morbidity and mortality in very-low-birth-weight (VLBW) infants. Study Design: This retrospective cohort study involved 15,765 VLBW infants born between 2003 and 2008 at less than 34 weeks of gestation and weighing less than 1,500 g at birth. Data were obtained from the Japanese neonatal research network database. Univariate and multivariate logistic regression analyses were performed to evaluate the impact of ACS and mode of delivery on the risk of infant mortality and morbidity. Results: Administration of ACS was associated with decreases in mortality rate, intraventricular hemorrhage (IVH) and retinopathy of prematurity (ROP), and was not associated with the incidence of respiratory distress syndrome (RDS), periventricular leukomalacia or necrotizing enterocolitis (NEC). When the administration of ACS was analyzed in the context of different modes of delivery, the incidence of IVH and ROP tended to decrease with cesarean section deliveries, whereas the incidence of RDS tended to decrease and the incidence of NEC tended to increase for infants delivered vaginally. The incidence of chronic lung disease tended to increase in association with both delivery methods. Conclusions: This large cohort study reconfirms that ACS treatment is associated with decreases in infant mortality and severe morbidity. Furthermore, the delivery method may be associated with severe morbidity in VLBW infants exposed to ACS.

1.
National Institutes of Health: Report of the consensus development conference on the effect of corticosteroids for fetal maturation on perinatal outcomes. Bethesda, US Department of Health and Human Services, National Institutes of Health, 1994, pub. No. 95-3784.
2.
Roberts D, Dalziel S: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006;3:CD004454.
3.
Miracle X, Di Renzo GC, Stark A, Fanaroff A, Carbonell-Estrany X, Saling E, Coordinators of WAPM Prematurity Working Group: Guideline for the use of antenatal corticosteroids for fetal maturation. J Perinat Med 2008;36:191-196.
4.
Kusuda S, Fujimura M, Sakuma I, Aotani H, Kabe K, Itani Y, et al: Morbidity and mortality of infants with very low birth weight in Japan: center variation. Pediatrics 2006;118: e1130-e1138.
5.
Mori R, Kusuda S, Fujimura M, Neonatal Research Network Japan: Antenatal corticosteroids promote survival of extremely preterm infants born at 22 to 23 weeks of gestation. J Pediatr 2011;159:110-114.
6.
Lee HC, Gould J: Survival advantage associated with cesarean delivery in very low birth weight vertex neonates. Obstet Gynecol 2006;107:97-105.
7.
Bottoms SF, Paul RH, Mercer BM, MacPherson CA, Caritis SN, Moawad AH, et al: Obstetric determinants of neonatal survival: antenatal predictors of neonatal survival and morbidity in extremely low birth weight infants. Am J Obstet Gynecol 1999;180:665-669.
8.
Wilson-Costello D, Friedman H, Minich N, Siner B, Taylor G, Schluchter M, et al: Improved neurodevelopmental outcomes for extremely low birth weight infants in 2000-2002. Pediatrics 2007;119:37-45.
9.
Malloy MH: Impact of cesarean section on neonatal mortality rates among very preterm infants in the United States, 2000-2003. Pediatrics 2008;122:285-292.
10.
Durie DE, Sciscione AC, Hoffman MK, Mackley AB, Paul DA: Mode of delivery and outcomes in very low-birth-weight infants in the vertex presentation. Am J Perinatol 2011;28:195-200.
11.
Batton B, Burnett C, Verhulst S, Batton D: Extremely preterm infant mortality rates and cesarean deliveries in the United States. Obstet Gynecol 2011;118:43-48.
12.
Lee HC, Gould JB: Survival rates and mode of delivery for vertex preterm neonates according to small- or appropriate-for-gestational-age status. Pediatrics 2006;118:e1836-e1844.
13.
Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, et al: Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010;126:443-456.
14.
Pietz J, Achanti B, Lilien L, Stepka EC, Mehta SK: Prevention of necrotizing enterocolitis in preterm infants: a 20-year experience. Pediatrics 2007;119:e164-e170.
15.
Karna P, Muttineni J, Angell L, Karmaus W: Retinopathy of prematurity and risk factors: a prospective cohort study. BMC Pediatr 2005;5:18.
16.
Yinon Y, Mazkereth R, Rosentzweig N, Jarus-Hakak A, Schiff E, Simchen MJ: Growth restriction as a determinant of outcome in preterm discordant twins. Obstet Gynecol 2005;105:80-84.
17.
Garite TJ, Clark R, Thorp JA: Intrauterine growth restriction increases morbidity and mortality among premature neonates. Am J Obstet Gynecol 2004;191:481-487.
18.
Darlow BA, Hutchinson JL, Henderson-Smart DJ, Donoghue DA, Simpson JM, Evans NJ, et al: Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics 2005;115:990-996.
19.
Choi SJ, Song SE, Seo ES, Oh SY, Kim JH, Roh CR: The effect of single or multiple courses of antenatal corticosteroid therapy on neonatal respiratory distress syndrome in singleton versus twin pregnancies. Aust NZ J Obstet Gynaecol 2009;49:173-179.
20.
Turrentine MA, Wilson PD, Wilkins IA: A retrospective analysis of the effect of antenatal steroid administration on the incidence of respiratory distress syndrome in preterm twin pregnancies. Am J Perinatol 1996;13:351-354.
21.
McEvoy C, Schilling D, Spitale P, Peters D, O'Malley J, Durand M: Decreased respiratory compliance in infants less than or equal to 32 weeks' gestation, delivered more than 7 days after antenatal steroid therapy. Pediatrics 2008;121:e1032-e1038.
22.
Mizuno M, Takeba Y, Matsumoto N, Tsuzuki Y, Asoh K, Takagi M, et al: Antenatal glucocorticoid therapy accelerates ATP production with creatine kinase increase in the growth-enhanced fetal rat heart. Circ J 2010;74:171-180.
23.
Arai M: Antenatal glucocorticoid therapy for fetal heart development. Circ J 2010;74:47-48.
24.
Vinukonda G, Dummula K, Malik S, Hu F, Thompson CI, Csiszar A, et al: Effect of prenatal glucocorticoids on cerebral vasculature of the developing brain. Stroke 2010;41:1766-1773.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.